Core Insights - Metagenomi, Inc. is focused on developing curative therapeutics using its proprietary gene editing toolbox, emphasizing the precision and safety of its technologies [1][2][3] Group 1: Gene Editing Technologies - MGX-001, a candidate for hemophilia A, utilizes the MG29-1 nuclease and shows no identifiable off-target editing, confirmed through various assays [2] - The MG29-1 nuclease targeting the albumin safe harbor locus demonstrated no evidence of translocations in primary human hepatocytes [2] - Metagenomi's adenine base editor (ABE) for ex vivo cell therapy showed no detectable translocations and no significant genomic base composition differences in primary T-cells compared to unedited cells [2] Group 2: Company Overview - Metagenomi leverages metagenomics to develop a comprehensive toolbox for genome editing, which includes programmable nucleases, base editors, and integration systems [3] - The company aims to correct any type of genetic mutation found in the genome, utilizing four billion years of microbial evolution [3] - Metagenomi's diverse and modular toolbox is designed to access the entire genome and select optimal tools for effective genome editing [3]
Metagenomi Presents Highly Specific and Efficient Genome Editing Tools at Nature Conference “RNA at the Bench and Bedside IV”